Clinical trials: Type 2 Diabetes Risk
Diabetes Mellitus Type II
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.
- Trial name
- NCT01565096
- Testing
- Metformin, Vildagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- ikfe-CRO GmbH
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Disease, Diabetes Mellitus Type 2
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose…
- Trial name
- NCT01715818
- Testing
- aleglitazar
- Where
- 392 sites in United States, Argentina and 25 more
- Volunteers
- 1,999 people
- Sponsor
- Hoffmann-La Roche
Prediabetes
Effects of Yoghurt Consumption on Glucose Metabolism in Prediabetic Subjects
The purpose of this study is to explore the effects of yoghurt consumption on glucose metabolism in prediabetic subjects.
- Trial name
- SNOWFALL (NCT06836752)
- Testing
- Yoghurt, Milk
- Where
- France
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Screening for Early Evidence of Diabetes
This is a pivotal study to determine the accuracy of a new device (SCOUT) in screening persons for pre-diabetes or diabetes. SCOUT will be compared to the standard screening test (Fasting Plasma Glucose), using the Oral Glucose…
- Trial name
- SEED (NCT00614783)
- Where
- 15 sites in United States
- Volunteers
- 3,478 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.
- Trial name
- NCT01086293
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Insulin-requiring Type 2 Diabetes Mellitus
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.
- Trial name
- NCT01500850
- Testing
- nph insulin, human insulin, Insulin Glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- ikfe-CRO GmbH
Prediabetic State, Diabetes type2
Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)
This clinical study aims to assess the efficacy of TOTUM-63, a mix of 5 plant extracts, consumed at the daily regimen of three times per day on glucose and lipid homeostasis in dysglycemic subjects.
- Conditions
- Prediabetic State, Diabetes type2, Dysglycemia
- Trial name
- REVERSE-IT (NCT04423302)
- Testing
- TOTUM-63 3 intakes per day, TOTUM-63 2 intakes per day
- Where
- 52 sites in Bulgaria, France and 5 more
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
- Trial name
- FINEXPLORER (NCT07554469)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Bayer
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2, Obesity
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk
- Trial name
- NCT07673822
- Testing
- No treatment given
- Where
- South Korea
- Volunteers
- 800,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone…
- Trial name
- NCT06649162
- Where
- 2 sites in South Korea
- Volunteers
- 10,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04957914
- Testing
- Insulin Glargine, LY3209590
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)
The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback…
- Trial name
- NCT02194608
- Testing
- Home telehealth system
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, Diabetes
Developing a Model to Better Predict Diabetes and/or Risk of Developing Diabetes
Participants who were previously Viome costumers who signed informed consent to participate and self reported type 2 diabetes or pre-diabetes were enrolled.
- Conditions
- Diabetes Type 2, Diabetes, Pre-diabetes
- Trial name
- NCT04905485
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 2,912 people, healthy volunteers welcome
- Sponsor
- Viome